Several highly pathogenic viruses, including SARS-CoV-2, share a conserved mechanism of infection via the fusion of the viral and host membranes employing a six-helix bundle (6-HB) heptad repeat.

Researchers at Dana-Farber Cancer Institute are advancing a fourth-generation allosteric EGFR inhibitor, EAI-432, to treat non-small-cell lung cancer driven by mutations in the EGFR gene, particularly the L858R mutation.

A new study from Dana Farber Cancer Institute, Brigham and Women’s Hospital and Poland’s Medical University of Lodz suggests a simple blood test could detect ovarian and breast cancer without the need for genetic sequencing, paving the way for broader and less costly screening campaigns.

Previous research demonstrated that the formation of PTEN-null tumors usually depends on the p100β catalytic isoform of PI3K (PI3Kβ); however, the mechanisms behind this dependency are unknown. In a recently published study, researchers from Dana-Farber Cancer Institute aimed to assess the role of PI3Kβ in immune evasion in PTEN-null breast cancer.

As prostate cancer progresses, tumors lose the androgen receptor (AR) on which initial treatment is based. Oftentimes, such patients also lose expression prostate-specific membrane antigen (PSMA), which is the target of approved agent Pluvicto (lutetium (177Lu) vipivotide tetraxetan; Novartis AG) as well as a number of experimental drugs. Such patients can no longer benefit from either androgen- or PSMA-directed therapy.